あなたのチームの研究ワークフローで動くPaperguideを
ひとつにつながったワークスペースでチームが研究を検索・整理・統合し、厳密で監査可能なシステマティックレビューをともに進める様子をご覧いただけます。
世界の主要研究機関のチームを含む、974,000人以上の研究者に信頼されています








最初の検索から引用付きの下書きまで、精査に耐える研究を
以下のすべてが、あなた自身の研究の問いを題材に、ひとつにつながったワークスペースで動きます。
- ZoteroやMendeleyからのインポート、DOIによる論文追加に対応。メタデータとオープンアクセスPDFは自動で取得されます。
- 論文を読み、注釈を付け、メモを各論文に紐づけたまま、プロジェクトをまたいで管理できます。
- ライブラリに質問すれば、リサーチエージェントが引用に基づいた回答を返します。
- 保存したすべての論文を、検索・レビュー・データ抽出・執筆で活用できます。

In practice

<1 weekfor a 2,000-paper PRISMA review
A 2,000-paper PRISMA review screened and extracted in a fraction of the time, without loosening the criteria.Read case study

6 weeksfor a review that took 3 months
A meta-analysis that surfaced contradictions a manual review would have missed, in half the time.Read case study

~60%faster screening cycles
Dual-screened SLR screening cut from about three weeks to one, with independent review and PRISMA intact.Read case study

Every decisionlogged with its criterion and evidence
CER literature reviews where every exclusion maps to a criterion an auditor can follow, with a complete decision log built in.Read case study
研究者の声
Paperguide not only enables the search for scientific articles but also provides a comprehensive systematic evaluation of the search results... it leads to significant time savings and better results, because one is "forced" to adopt a systematic approach from the start.
Matthias R.Lecturer, LfBA
The demo ran a full review on our own topic. Seeing the dual screening and the PRISMA output on a real question is what convinced the team to move.
Karin V.Head of Evidence Synthesis
We deliver more reviews per analyst than we did a year ago. Screening and extraction used to eat the timeline; now they are the fastest parts, and that shows up directly in how many client projects we can take on.
Jonas W.Director of Evidence Synthesis
When an auditor asks why a study was excluded, the answer is one click away: the criterion, the evidence, and the person who confirmed it. We stopped rebuilding the audit trail at the end of every review.
Daniel K.Clinical Evidence Lead